Shaolong Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaolong Zhu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Camille Houy
Analytical Sciences, Sanofi Vaccines Canada Ltd, 1755 Steeles Avenue West, Toronto, ON M2R 3T4, Canada
3 shared publications- Derek J. Wilson
Department of Chemistry, York University, Toronto, ON M3J 1P3, Canada
3 shared publications Tricia Chen
Analytical Sciences Sanofi Pasteur Ltd Toronto Ontario Canada
3 shared publications- D. Andrew James
External Research and Development, Sanofi, 1755 Steeles Avenue West, Toronto, ON M2R 3T4, Canada
2 shared publications Jason Szeto
Analytical Sciences, Sanofi Vaccines Canada Ltd, 1755 Steeles Avenue West, Toronto, ON M2R 3T4, Canada
2 shared publicationsLuciano Ettorre
Analytical Sciences, Sanofi Vaccines Canada Ltd, 1755 Steeles Avenue West, Toronto, ON M2R 3T4, Canada
2 shared publications
Latest Publications
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (11) , 3227-3238
HDX-MS epitope characterization for evaluating antibody suitability for ELISA-based in vitro potency testing of vaccines
ELISA requirements: a crosslinked toxoid presents immune epitopes. Antibodies are screened by hydrogen deuterium exchange. Antibodies targeting separated neutralizing epitopes support in vitro potency testing, replacing in vivo .
- 20 April 2026
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (11) , 3227-3238
HDX-MS epitope characterization for evaluating antibody suitability for ELISA-based in vitro potency testing of vaccines
ELISA requirements: a crosslinked toxoid presents immune epitopes. Antibodies are screened by hydrogen deuterium exchange. Antibodies targeting separated neutralizing epitopes support in vitro potency testing, replacing in vivo .
- 8 November 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (2) , 2100358
Epitope screening using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS): An accelerated workflow for evaluation of lead monoclonal antibodies
Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production have enabled candidate mAbs to be identified at a rapidly increasing rate, resulting in a significant bottleneck in the characterization of “structural” epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, a Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen.Main methods and major results: The method is demonstrated on set of six candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes were unambiguously determined using two HDX mixing timepoints in 24 h total run time, which is equivalent to the instrument time required to map a single epitope using the conventional workflow.Conclusion: An accelerated HDX‐MS epitope screening workflow was developed. The “screening” workflow successfully characterized five (out of six attempted) novel epitopes on the PRN antigen; information that can be used to support vaccine antigenicity assays.
- 8 November 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (2) , 2100358
Epitope screening using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS): An accelerated workflow for evaluation of lead monoclonal antibodies
Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production have enabled candidate mAbs to be identified at a rapidly increasing rate, resulting in a significant bottleneck in the characterization of “structural” epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, a Hydrogen/Deuterium Exchange Mass Spectrometry (HDX‐MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen.Main methods and major results: The method is demonstrated on set of six candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes were unambiguously determined using two HDX mixing timepoints in 24 h total run time, which is equivalent to the instrument time required to map a single epitope using the conventional workflow.Conclusion: An accelerated HDX‐MS epitope screening workflow was developed. The “screening” workflow successfully characterized five (out of six attempted) novel epitopes on the PRN antigen; information that can be used to support vaccine antigenicity assays.
- Open Access
- 27 July 2021
- Published by Wiley
Epitope Screening Using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): An Optimized Workflow for Accelerated Evaluation of Lead Monoclonal Antibodies
Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production has enabled candidate mAbs to be identified at a rapidly increasing rate resulting in a significant bottleneck in the characterization of ‘structural’ epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen. Main methods and major results: The method is demonstrated on set of 6 candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes was unambiguously determined using two HDX mixing timepoints in 24 hours total run time, corresponding to substantial decrease in the instrument time required to map a single epitope using conventional HDX workflows. Conclusion: An accelerated HDX-MS epitope screening workflow was developed. The two-timepoint ‘screening’ workflow mapped all six mAbs and generated high confidence epitopes for five of the six mAbs assayed. The substantial improvement in the rate of data collection can advance HDX-MS for higher throughput investigations supporting the ability to evaluate a broader number of mAb candidates at an earlier stage of vaccine development.
- 27 July 2021
- Published by Wiley
Open AccessEpitope Screening Using Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS): An Optimized Workflow for Accelerated Evaluation of Lead Monoclonal Antibodies
Background: Epitope mapping is an increasingly important aspect of biotherapeutic and vaccine development. Recent advances in therapeutic antibody design and production has enabled candidate mAbs to be identified at a rapidly increasing rate resulting in a significant bottleneck in the characterization of ‘structural’ epitopes, that are challenging to determine using existing high throughput epitope mapping tools. Here, Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS) epitope screening workflow was introduced that is well suited for accelerated characterization of epitopes with a common antigen. Main methods and major results: The method is demonstrated on set of 6 candidate mAbs targeting Pertactin (PRN). Using this approach, five of the six epitopes was unambiguously determined using two HDX mixing timepoints in 24 hours total run time, corresponding to substantial decrease in the instrument time required to map a single epitope using conventional HDX workflows. Conclusion: An accelerated HDX-MS epitope screening workflow was developed. The two-timepoint ‘screening’ workflow mapped all six mAbs and generated high confidence epitopes for five of the six mAbs assayed. The substantial improvement in the rate of data collection can advance HDX-MS for higher throughput investigations supporting the ability to evaluate a broader number of mAb candidates at an earlier stage of vaccine development.
- 18 December 2018
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 58 (6) , 646-656
Hydrogen–Deuterium Exchange Epitope Mapping Reveals Distinct Neutralizing Mechanisms for Two Monoclonal Antibodies against Diphtheria Toxin
The Diphtheria toxoid (DT) antigen is one of the major components in pediatric and booster combination vaccines and is known to raise a protective humoral immune response upon vaccination. However, a structurally resolved analysis of Diphtheria toxin (DTx) epitopes with underlying molecular mechanisms of antibody neutralization has not yet been reported. Using hydrogen deuterium exchange mass spectrometry (HDX-MS) and Bio-Layer Interferometry (BLI) assays, we have characterized two neutralizing anti-DTx monoclonal antibodies (mAbs), 2-25 and 2-18, by identifying the specific epitopes on Diphtheria toxin responsible for antibody binding. Our results show that both epitopes are conformational, and mechanistically distinct. mAb 2-25 binds selectively to the B-subunit (translocation and receptor domain) of DTx, blocking the Heparin-binding EGF-like growth factor (HBEGF) binding site. In contrast, mAb 2-18 binds to the A-subunit (catalytic domain), partially covering the catalytic loop region that shuttles NAD during catalysis. The results are discussed in the context of antigen neutralization mechanisms and can ultimately help to reveal the underlying factors that contribute to Diptheria vaccine efficacy.
- 18 December 2018
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 58 (6) , 646-656
Hydrogen–Deuterium Exchange Epitope Mapping Reveals Distinct Neutralizing Mechanisms for Two Monoclonal Antibodies against Diphtheria Toxin
The Diphtheria toxoid (DT) antigen is one of the major components in pediatric and booster combination vaccines and is known to raise a protective humoral immune response upon vaccination. However, a structurally resolved analysis of Diphtheria toxin (DTx) epitopes with underlying molecular mechanisms of antibody neutralization has not yet been reported. Using hydrogen deuterium exchange mass spectrometry (HDX-MS) and Bio-Layer Interferometry (BLI) assays, we have characterized two neutralizing anti-DTx monoclonal antibodies (mAbs), 2-25 and 2-18, by identifying the specific epitopes on Diphtheria toxin responsible for antibody binding. Our results show that both epitopes are conformational, and mechanistically distinct. mAb 2-25 binds selectively to the B-subunit (translocation and receptor domain) of DTx, blocking the Heparin-binding EGF-like growth factor (HBEGF) binding site. In contrast, mAb 2-18 binds to the A-subunit (catalytic domain), partially covering the catalytic loop region that shuttles NAD during catalysis. The results are discussed in the context of antigen neutralization mechanisms and can ultimately help to reveal the underlying factors that contribute to Diptheria vaccine efficacy.